NeOnc Technologies (NTHI) announced that its global patent portfolio totals 176, reinforcing its competitive position. The Company’s IP portfolio, covering its core pipeline, currently comprises 126 issued patents – 29 in the United States and 97 internationally; and 50 pending patents – 19 in the United States and 31 internationally. The Company’s IP protections span all major pharmaceutical markets, including the U.S., European Union, China, Japan, Brazil, and Australia, as the Company advances its portfolio of next-generation therapeutics toward regulatory approval.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NTHI:
- NeOnc Technologies expects full enrollment in Phase 2a trial of NEO100-01
- NeOnc Technologies Appoints New President Amid Strategic Moves
- NeOnc Technologies appoints Heshmatpour as President
- NeOnc Technologies announces NEO212 trial nears full enrollment
- Neonc Technologies Holdings Inc trading resumes